Compare Johnson & Johnson (JNJ) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Match Group Inc — how do they compare? Johnson & Johnson trades at $249.26 (market cap $598.96B), while Match Group Inc trades at $38.8 (market cap $9.10B). The key difference: Johnson & Johnson is far larger — about 65.8× Match Group Inc's market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | MTCH | |
|---|---|---|
Market Cap | $598.96B | $9.10B |
Volume | 6,156,228 | — |
Sector | Health | Media |
52-Week High | $267.24 | $40.29 |
52-Week Low | $164.36 | $28.90 |
Enterprise Value | $631.90B | $12.05B |
Dividend Yield | 2.15% | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
MTCH trades at $39.10, down 0.13% today, with a bullish technical outlook supported by moving averages and key resistance at $40. The company reported Q1 2026 revenue growth of 4% but missed EPS expectations. Strong profitability is evident with a 73.8% gross margin and 17.59% net margin. Recent news highlights Tinder's turnaround efforts and Hinge's growth, with Q2 2026 earnings due August 4, 2026.
The stock presents a moderate buy opportunity with a consensus price target of $41.63, offering ~6% upside. Risks include Tinder's user declines and high debt levels, but valuation multiples like a P/E of 14.94 suggest potential undervaluation. Investor sentiment is positive, with no analyst sell ratings, though execution on user growth remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
